NT-503-3 / Neurotech Pharma - LARVOL DELTA

Neurotech announces renewed focus on NT‐501 (CNTF) encapsulated cell therapy clinical programs (Neurotech Press Release) - "Neurotech Pharmaceuticals, Inc. today announced that the company will focus all future clinical efforts on their Phase 2 NT-501 programs...This change in strategic direction follows the decision to halt the Phase 2 study of a soluble anti vascular endothelial growth factor (anti-VEGF) receptor protein delivered by ECT (NT-503) for the treatment of wet AMD...A Phase 2 trial of CNTF in MacTel is underway in 66 patients (99 eyes), and two-year data is expected in the second quarter of 2017."

Anticipated P2 data • Trial suspension • Glaucoma • Ophthalmology

Innovative therapies for neovascular age-related macular degeneration. (PubMed, Expert Opin Pharmacother) - "Expert opinion: Long-acting anti-VEGF agents have demonstrated promising results in phase 3 studies, and include Brolucizumab, a single-chain antibody fragment, and Abicipar, a designed ankyrin repeat protein (DARPin). Other unique anti-VEGF agents in current trials include Conbercept - a fusion protein of the VEGF receptor domains, KSI-301 - an anti-VEGF antibody biopolymer conjugate, and OPT-302 - an inhibitor of VEGF-C/D. Strategies to activate the Tie-2 receptor, some in combination with VEGF inhibition, are of interest, with recent trials of Faricimab, ARP-1536, and nesvacumab. Topical anti-VEGF ± anti-PDGF agents, such as pazopanib, squalamine lactate, regorafenib, and LHA510 have shown limited efficacy and/or have not been advanced, although PAN-90806 continues to advance with promising initial results. Sustained-release anti-VEGF treatments, to address treatment burden, include the ranibizumab Port Delivery System, GB-102, NT-503, hydrogel depot,..."

Journal